A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer

Background Sequencing of both healthy and disease singletons yields many novel and low frequency variants of uncertain significance (VUS). Complete gene and genome sequencing by next generation sequencing (NGS) significantly increases the number of VUS detected. While prior studies have emphasized protein coding variants, non-coding sequence variants have also been proven to significantly contribute to high penetrance disorders, such as hereditary breast and ovarian cancer (HBOC). We present a strategy for analyzing different functional classes of non-coding variants based on information theory (IT). Methods We captured and enriched for coding and non-coding variants in genes known to harbor mutations that increase HBOC risk. Custom oligonucleotide baits spanning the complete coding, non-coding, and intergenic regions 10 kb up- and downstream of ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, and TP53 were synthesized for solution hybridization enrichment. Unique and divergent repetitive sequences were sequenced in 102 high-risk patients without identified mutations in BRCA1/2. Aside from protein coding changes, IT-based sequence analysis was used to identify and prioritize pathogenic non-coding variants that occurred within sequence elements predicted to be recognized by proteins or protein complexes involved in mRNA splicing, transcription, and untranslated region (UTR) binding and structure. This approach was supplemented by in silico and laboratory analysis of UTR structure. Results 15,311 unique variants were identified, of which 245 occurred in coding regions. With the unified IT-framework, 132 variants were identified and 87 functionally significant VUS were further prioritized. We also identified 4 stop-gain variants and 3 reading-frame altering exonic insertions/deletions (indels). Conclusions We have presented a strategy for complete gene sequence analysis followed by a unified framework for interpreting non-coding variants that may affect gene expression. This approach distills large numbers of variants detected by NGS to a limited set of variants prioritized as potential deleterious changes.

[1]  Gary D. Stormo,et al.  Delila system tools , 1984, Nucleic Acids Res..

[2]  T. D. Schneider,et al.  Information content of binding sites on nucleotide sequences. , 1986, Journal of molecular biology.

[3]  D. Pinkel,et al.  Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. D. Schneider,et al.  Sequence logos: a new way to display consensus sequences. , 1990, Nucleic acids research.

[5]  B. Vogelstein,et al.  Inherited p53 gene mutations in breast cancer. , 1992, Cancer research.

[6]  R. Reed,et al.  The prespliceosome components SAP 49 and SAP 145 interact in a complex implicated in tethering U2 snRNP to the branch site. , 1994, Genes & development.

[7]  D S Latchman,et al.  Transcription-factor mutations and disease. , 1996, The New England journal of medicine.

[8]  D. Lancet,et al.  GeneCards: integrating information about genes, proteins and diseases. , 1997, Trends in genetics : TIG.

[9]  D. Evans,et al.  Li-Fraumeni syndrome--a molecular and clinical review. , 1997, British Journal of Cancer.

[10]  T. D. Schneider,et al.  Information content of individual genetic sequences. , 1997, Journal of theoretical biology.

[11]  Å. Borg,et al.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. , 1997, American journal of human genetics.

[12]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[13]  T. D. Schneider,et al.  Information analysis of human splice site mutations , 1998, Human mutation.

[14]  Sara G. Becker-Catania,et al.  Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. , 1999, American journal of human genetics.

[15]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[16]  D. Durocher,et al.  The FHA domain is a modular phosphopeptide recognition motif. , 1999, Molecular cell.

[17]  X. Estivill,et al.  Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. , 2000, Human molecular genetics.

[18]  Jing Chen,et al.  Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.

[19]  D. Sgroi,et al.  Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. , 2001, Cancer research.

[20]  C Caldas,et al.  Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.

[21]  J. Peto.  Breast cancer susceptibility-A new look at an old model. , 2002, Cancer cell.

[22]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[23]  R. Ellis.  International Consensus Conference on Breast Cancer. , 2002, Journal of the American College of Surgeons.

[24]  A. Kornblihtt,et al.  Alternative splicing: multiple control mechanisms and involvement in human disease. , 2002, Trends in genetics : TIG.

[25]  T. Rebbeck,et al.  Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? , 2003, Journal of Medical Genetics.

[26]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[27]  R. Eeles,et al.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.

[28]  J. Steven Leeder,et al.  Genome-wide prediction, display and refinement of binding sites with information theory-based models , 2003, BMC Bioinformatics.

[29]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[30]  N. Gueven,et al.  Site‐directed mutagenesis of the ATM promoter: Consequences for response to proliferation and ionizing radiation , 2003, Genes, chromosomes & cancer.

[31]  Peter K Rogan,et al.  Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. , 2003, Pharmacogenetics.

[32]  S. Plon,et al.  A Risky Business--Assessing Breast Cancer Risk , 2003, Science.

[33]  Christopher G Mathew,et al.  Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. , 2004, Human molecular genetics.

[34]  Hiroki Inui,et al.  Two essential splice lariat branchpoint sequences in one intron in a xeroderma pigmentosum DNA repair gene: mutations result in reduced XPC mRNA levels that correlate with cancer risk. , 2003, Human molecular genetics.

[35]  C. Misquitta,et al.  The role of 3′-untranslated region (3′-UTR) mediated mRNA stability in cardiovascular pathophysiology , 2001, Molecular and Cellular Biochemistry.

[36]  Debajit K. Biswas,et al.  NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .

[37]  P. Rogan,et al.  Bipartite pattern discovery by entropy minimization-based multiple local alignment. , 2004, Nucleic acids research.

[38]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[39]  W. Foulkes,et al.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.

[40]  Patrick S. Schnable,et al.  Picky: oligo microarray design for large genomes , 2004, Bioinform..

[41]  David L. Wheeler,et al.  GenBank: update , 2004, Nucleic Acids Res..

[42]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[43]  Yongjian Guo,et al.  The distribution of SNPs in human gene regulatory regions , 2005, BMC Genomics.

[44]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[46]  D. Reisman,et al.  Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter , 2006, Oncogene.

[47]  P. Rogan,et al.  Predicting severity of haemophilia A and B splicing mutations by information analysis , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[48]  D. Easton,et al.  Models of genetic susceptibility to breast cancer , 2006, Oncogene.

[49]  Alfons Meindl,et al.  Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study , 2006, BMC Cancer.

[50]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[51]  L. Shkreta,et al.  hnRNP I/PTB can antagonize the splicing repressor activity of SRp30c. , 2007, RNA.

[52]  D. Cane,et al.  The nonsense-mediated decay RNA surveillance pathway. , 2007, Annual review of biochemistry.

[53]  S. Gruber,et al.  Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. , 2007, JAMA.

[54]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[55]  C. Sander,et al.  Determinants of protein function revealed by combinatorial entropy optimization , 2007, Genome Biology.

[56]  P. Miron,et al.  Germline E-cadherin mutations in familial lobular breast cancer , 2007, Journal of Medical Genetics.

[57]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[58]  B. Fernandez,et al.  Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.

[59]  S. Chattopadhyay,et al.  Stabilization of SMAR1 mRNA by PGA2 involves a stem–loop structure in the 5′ UTR , 2007, Nucleic acids research.

[60]  Michael Zuker,et al.  UNAFold: software for nucleic acid folding and hybridization. , 2008, Methods in molecular biology.

[61]  B. Weber,et al.  Genetic variants of uncertain significance: flies in the ointment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[63]  W. Otten,et al.  The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life , 2008, Psycho-oncology.

[64]  T. Stankovic,et al.  Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients , 2008, British journal of haematology.

[65]  Nancy F. Hansen,et al.  Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.

[66]  J. Tazi,et al.  A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects , 2008, Human mutation.

[67]  C. Vaurs-Barrière,et al.  PLP1 splicing abnormalities identified in Pelizaeus‐Merzbacher disease and SPG2 fibroblasts are associated with different types of mutations , 2008, Human mutation.

[68]  Paolo Boffetta,et al.  Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group , 2008, Human mutation.

[69]  S. Tavtigian,et al.  In silico analysis of missense substitutions using sequence‐alignment based methods , 2008, Human mutation.

[70]  Arshad Khan,et al.  SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms , 2008, Bioinform..

[71]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[72]  E. Bertini,et al.  Identification and characterization of novel collagen VI non‐canonical splicing mutations causing ullrich congenital muscular dystrophy , 2009, Human mutation.

[73]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[74]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[75]  K. Gardner,et al.  Transcriptional regulation of BRCA1 expression by a metabolic switch , 2010, Nature Structural &Molecular Biology.

[76]  E. Buratti,et al.  Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies , 2010, The FEBS journal.

[77]  Hong Ding,et al.  Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls , 2010, Breast Cancer Research and Treatment.

[78]  Alain Laederach,et al.  Disease-Associated Mutations That Alter the RNA Structural Ensemble , 2010, PLoS genetics.

[79]  J. Holt,et al.  Impact of RING and BRCT Domain Mutations on BRCA1 Protein Stability, Localization and Recruitment to DNA Damage , 2010, Radiation research.

[80]  A. Børresen-Dale,et al.  Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study , 2010, Human mutation.

[81]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[82]  J. Pal,et al.  Pathological Variations in 3′-untranslated Regions of Human Genes , 2010 .

[83]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[84]  T. Cooper,et al.  The pathobiology of splicing , 2010, The Journal of pathology.

[85]  T. Frebourg,et al.  The BRCA1 c.5434C→G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements , 2010, Journal of Medical Genetics.

[86]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[87]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[88]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[89]  E. Mucaki,et al.  Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants , 2011, Human mutation.

[90]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[91]  Graham M Lord,et al.  Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension , 2011, Human mutation.

[92]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[93]  K. Carleton.  Quantification of transcript levels with quantitative RT-PCR. , 2011, Methods in molecular biology.

[94]  A. W. van der Vaart,et al.  CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women , 2011, Journal of Medical Genetics.

[95]  H R Garner,et al.  Evaluation of microsatellite variation in the 1000 Genomes Project pilot studies is indicative of the quality and utility of the raw data and alignments. , 2011, Genomics.

[96]  K. Weeks,et al.  Selective 2′-hydroxyl acylation analyzed by protection from exoribonuclease (RNase-detected SHAPE) for direct analysis of covalent adducts and of nucleotide flexibility in RNA , 2011, Nature Protocols.

[97]  O. Olopade,et al.  c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells , 2011, BMC Cancer.

[98]  Eliseos J. Mucaki,et al.  Population Fitness and Genetic Load of Single Nucleotide Polymorphisms Affecting mRNA splicing , 2011, 1107.0716.

[99]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[100]  Kate B. Cook,et al.  RBPDB: a database of RNA-binding specificities , 2010, Nucleic Acids Res..

[101]  C. Begg,et al.  Rare germline mutations in PALB2 and breast cancer risk: A population‐based study , 2012, Human mutation.

[102]  Shankar Balasubramanian,et al.  Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells , 2013, Genome Biology.

[103]  D. Jong,et al.  Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance , 2012, Familial Cancer.

[104]  D. Kavanagh,et al.  Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome. , 2012, Kidney international.

[105]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[106]  G. Hankins,et al.  Structure-Function of the Tumor Suppressor BRCA1 , 2012, Computational and structural biotechnology journal.

[107]  M. Simpson,et al.  Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). , 2012, The Journal of investigative dermatology.

[108]  Christopher A Cassa,et al.  Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. , 2012, Genome research.

[109]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[110]  J. Valcárcel,et al.  hnRNP A1 proofreads 3' splice site recognition by U2AF. , 2012, Molecular cell.

[111]  Yongwook Choi,et al.  A fast computation of pairwise sequence alignment scores between a protein and a set of single-locus variants of another protein , 2012, BCB.

[112]  Leslie G. Biesecker,et al.  Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project , 2012, Genetics in Medicine.

[113]  Kihoon Yoon,et al.  Before It Gets Started: Regulating Translation at the 5′ UTR , 2012, Comparative and functional genomics.

[114]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[115]  Nicholas R. Lemoine,et al.  SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update) , 2012, Nucleic Acids Res..

[116]  Johnny S. H. Kwan,et al.  A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases , 2012, Nucleic acids research.

[117]  Zhenqing Ye,et al.  Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3 , 2012, Genome Biology.

[118]  R. Wolff,et al.  Associations between TCF7L2 polymorphisms and risk of breast cancer among Hispanic and non-Hispanic White women: the Breast Cancer Health Disparities Study , 2012, Breast Cancer Research and Treatment.

[119]  Eric Rivals,et al.  CRAC: an integrated approach to the analysis of RNA-seq reads , 2013, Genome Biology.

[120]  William Stafford Noble,et al.  Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors , 2012, Genome research.

[121]  Jing Chen,et al.  Interactions of Nucleolin and Ribosomal Protein L26 (RPL26) in Translational Control of Human p53 mRNA* , 2012, The Journal of Biological Chemistry.

[122]  Peter K. Rogan,et al.  Interpretation, Stratification and Evidence for Sequence Variants Affecting mRNA Splicing in Complete Human Genome Sequences , 2013, Genom. Proteom. Bioinform..

[123]  Bernd Fischer,et al.  RNA-binding proteins in Mendelian disease. , 2013, Trends in genetics : TIG.

[124]  Peter K. Rogan,et al.  Expanding probe repertoire and improving reproducibility in human genomic hybridization , 2013, Nucleic acids research.

[125]  Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin , 2014, Molecular Biology Reports.

[126]  Nicholas R. Lemoine,et al.  A practical guide for the functional annotation of genetic variations using SNPnexus , 2013, Briefings Bioinform..

[127]  Brendan J. Frey,et al.  A compendium of RNA-binding motifs for decoding gene regulation , 2013, Nature.

[128]  A. Sézeur,et al.  CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study , 2013, Journal of Medical Genetics.

[129]  Adam P. DeLuca,et al.  Non-exomic and synonymous variants in ABCA4 are an important cause of Stargardt disease , 2013, Human molecular genetics.

[130]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[131]  E. Velasco,et al.  Evaluating the effect of unclassified variants identified in MMR genes using phenotypic features, bioinformatics prediction, and RNA assays. , 2013, The Journal of molecular diagnostics : JMD.

[132]  Tao Yuan,et al.  Association between TCF7L2 Gene Polymorphism and Cancer Risk: A Meta-Analysis , 2013, PloS one.

[133]  S. Fuqua,et al.  Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing , 2013, Scientific Reports.

[134]  F. Collins,et al.  First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.

[135]  K. Offit,et al.  Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  Eliseos J Mucaki,et al.  Prediction of Mutant mRNA Splice Isoforms by Information Theory‐Based Exon Definition , 2013, Human mutation.

[137]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[138]  S. Radulović,et al.  Serbian high-risk families: extensive results on BRCA mutation spectra and frequency , 2013, Journal of Human Genetics.

[139]  J. Fei,et al.  Splice Site Mutation-Induced Alteration of Selective Regional Activity Correlates with the Role of a Gene in Cardiomyopathy , 2013 .

[140]  C. Maier,et al.  Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations , 2014, The Prostate.

[141]  Yuya Kobayashi,et al.  Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  Ben C. Shirley,et al.  Validation of predicted mRNA splicing mutations using high-throughput transcriptome data. , 2014, F1000Research.

[143]  Peter K. Rogan,et al.  Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis , 2014, F1000Research.

[144]  T. Frebourg,et al.  Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes , 2014, European Journal of Human Genetics.

[145]  Karin S Kassahn,et al.  Integrating Massively Parallel Sequencing into Diagnostic Workflows and Managing the Annotation and Clinical Interpretation Challenge , 2014, Human mutation.

[146]  Nicole Soranzo,et al.  Functional interpretation of non-coding sequence variation: Concepts and challenges , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.

[147]  Lingjia Tang,et al.  A novel variant in the 3′ UTR of human SCN1A gene from a patient with Dravet syndrome decreases mRNA stability mediated by GAPDH’s binding , 2014, Human Genetics.

[148]  Dong-Yun Kim,et al.  Discretized Gaussian mixture for genotyping of microsatellite loci containing homopolymer runs , 2014, Bioinform..

[149]  Kate B. Cook,et al.  Determination and Inference of Eukaryotic Transcription Factor Sequence Specificity , 2014, Cell.

[150]  Jane E. Carpenter,et al.  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. , 2014, Carcinogenesis.

[151]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[152]  Eliseos J. Mucaki,et al.  FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. , 2015, Human molecular genetics.

[153]  C. Ponting,et al.  RBFOX and PTBP1 proteins regulate the alternative splicing of micro-exons in human brain transcripts , 2015, Genome research.

[154]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[155]  T. Ross,et al.  Use of panel tests in place of single gene tests in the cancer genetics clinic , 2015, Clinical genetics.

[156]  K. Hitomi,et al.  Lamellar ichthyosis with pseudoexon activation in the transglutaminase 1 gene , 2015, The Journal of dermatology.

[157]  Angela DeMichele,et al.  Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer , 2014, Genetics in Medicine.

[158]  M. Mikuła,et al.  New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing , 2015, BMC Medical Genomics.

[159]  A. Toland,et al.  Use of Whole Genome Sequencing for Diagnosis and Discovery in the Cancer Genetics Clinic , 2014, EBioMedicine.

[160]  B. Monk,et al.  Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. , 2014, Gynecologic oncology.